Last updated: October 31, 2026
Pedmark is Fennec Pharmaceuticals' branded sodium thiosulfate injection for reducing the risk of cisplatin-associated ototoxicity in pediatric patients with localized, nonmetastatic solid tumors. The product received U.S. FDA approval in September 2022 and entered a concentrated specialty market with limited direct competition, high clinical need, and substantial dependence on pediatric oncology treatment protocols. Fennec's commercial outlook is driven by hospital adoption, treatment-center penetration, reimbursement, and the number of eligible cisplatin-treated children rather than broad primary-care prescribing.
What is Pedmark and which company markets it?
Pedmark is an intravenous sodium thiosulfate formulation administered after cisplatin chemotherapy. Fennec Pharmaceuticals developed and commercialized the product in the United States.
| Metric |
Details |
| Active ingredient |
Sodium thiosulfate |
| U.S. brand |
Pedmark |
| Sponsor |
Fennec Pharmaceuticals, Inc. |
| FDA application |
NDA 214909 |
| FDA approval |
September 20, 2022 |
| Indication |
Reduction of the risk of ototoxicity associated with cisplatin in pediatric patients one month of age and older with localized, nonmetastatic solid tumors |
| Administration |
Intravenous infusion after cisplatin |
| Primary commercial channel |
Pediatric oncology hospitals and treatment centers |
| Main competitor class |
Cisplatin otoprotection alternatives, supportive-care protocols, and off-label sodium thiosulfate use |
The FDA approval was based principally on data from the SIOPEL 6 and COG ACCL0431 studies. SIOPEL 6 evaluated sodium thiosulfate in children with standard-risk hepatoblastoma. ACCL0431 evaluated its use across several pediatric cancers. The trials demonstrated a reduction in hearing loss, although clinical use depends on tumor type, disease location, chemotherapy timing, and the treating center's protocol.[1]
How large is the Pedmark market?
The addressable market is specialized but commercially meaningful. Pedmark targets children receiving cisplatin for cancers such as hepatoblastoma, osteosarcoma, neuroblastoma, germ-cell tumors, and selected brain and other solid tumors.
The market has four structural characteristics:
- The patient population is small relative to adult oncology markets.
- Cisplatin use is concentrated in major pediatric cancer centers.
- Hearing loss is a serious long-term toxicity with substantial quality-of-life consequences.
- Adoption can expand when treatment guidelines, institutional protocols, and payer coverage recognize otoprotection as standard supportive care.
The commercial ceiling is constrained by the number of pediatric patients treated with cisplatin and by clinical exclusions. Pedmark is not positioned for all cisplatin recipients. The FDA label is limited to localized, nonmetastatic solid tumors, reflecting concerns that sodium thiosulfate could reduce cisplatin antitumor activity if administered in settings with residual or disseminated disease.
What drives Pedmark demand?
Demand depends on five factors:
- Pediatric oncology protocol adoption.
- Reimbursement by commercial insurers and government programs.
- Availability of pediatric audiology and oncology coordination.
- Physician acceptance of post-cisplatin administration.
- Institutional pharmacy and infusion-center purchasing.
The product benefits from a clear clinical problem. Cisplatin-related hearing loss can be permanent, may require hearing aids or cochlear implants, and can affect speech, education, and developmental outcomes. That burden supports use despite the product's incremental cost.
The principal adoption barrier is operational. Pedmark requires an additional infusion after cisplatin, creating pharmacy preparation, chair-time, nursing, and scheduling requirements. In some institutions, treatment protocols and workflow changes can delay adoption even when the clinical rationale is accepted.
What is Pedmark's financial trajectory?
Fennec moved from development-stage operations to commercial revenue after the 2022 FDA approval. Public filings show the financial model shifting from clinical-trial funding and regulatory execution to sales-force expansion, market access, manufacturing, and hospital account development.[2]
| Period |
Commercial status |
Financial significance |
| 2021 |
Pre-approval |
Development and regulatory spending dominated |
| 2022 |
FDA approval and U.S. launch |
Initial product revenue; launch expenses increased |
| 2023 |
First full commercial year |
Hospital adoption and payer access became primary growth drivers |
| 2024 onward |
Market expansion phase |
Revenue growth depends on treatment-center penetration and repeat protocol use |
Fennec's economic profile is more attractive than that of a conventional hospital product because the company can sell a differentiated, FDA-approved formulation into a focused market without maintaining a broad primary-care sales infrastructure. The tradeoff is the limited patient pool and concentration of revenue among specialized institutions.
The product's financial trajectory should be evaluated through the following indicators:
| Indicator |
Why it matters |
| Quarterly net product revenue |
Measures uptake and treatment-center expansion |
| Number of active accounts |
Shows breadth beyond early-adopter hospitals |
| Gross margin |
Reflects manufacturing scale and product economics |
| Sales and marketing expense |
Indicates the cost of converting pediatric oncology centers |
| Accounts receivable and payer mix |
Shows reimbursement quality and collection risk |
| Cash balance and operating cash flow |
Determines financing requirements |
| Commercial inventory |
Signals demand planning and supply-chain execution |
Fennec's revenue exposure is highly concentrated in Pedmark. That concentration creates operating leverage if sales increase, but it also creates material downside if adoption, reimbursement, or label expansion underperforms.
When does Pedmark lose exclusivity?
Pedmark's U.S. exclusivity is based on a combination of regulatory exclusivity and patent protection.
The FDA granted Pedmark orphan-drug designation before approval. Orphan-drug exclusivity generally prevents approval of another drug for the same indication for seven years from the approval date, subject to statutory exceptions. For Pedmark, the seven-year period would generally run from September 20, 2022, to September 20, 2029.[1]
The product also received pediatric exclusivity, which can add six months to qualifying FDA exclusivity periods if the sponsor satisfies the statutory requirements. The precise effect depends on the FDA's exclusivity records and the underlying patent and regulatory periods.
| Protection |
Approximate endpoint or relevance |
| FDA orphan-drug exclusivity |
Generally September 2029 |
| Pediatric exclusivity |
Potential six-month extension to applicable periods |
| Patents |
May extend beyond regulatory exclusivity |
| Patent-term adjustment |
Must be calculated from each issued patent and regulatory history |
Orphan exclusivity does not prevent every possible competitor. It generally blocks FDA approval of the same drug for the same orphan indication, but it does not necessarily prevent different formulations, different indications, or products that qualify under statutory exceptions.
What patents protect Pedmark?
The commercial protection strategy is expected to focus on the pharmaceutical formulation, dosing regimen, and use of sodium thiosulfate to reduce cisplatin-associated ototoxicity.
Potential patent categories include:
- Ready-to-use or concentrated sodium thiosulfate formulations.
- Stability and storage characteristics.
- Administration after cisplatin.
- Pediatric dosing regimens.
- Use in defined tumor populations.
- Manufacturing and product-quality controls.
The key commercial question is whether Fennec has issued patents listed for the approved product in the FDA Orange Book and whether those patents claim the product as sold rather than only a broad clinical concept. Patent scope is more valuable when it covers the commercial formulation and administration sequence.
What is the Orange Book status of Pedmark?
Pedmark is approved under NDA 214909. Orange Book protection should be assessed by reviewing the current FDA listing for the NDA, including any patent numbers, use codes, and pediatric-exclusivity entries.[3]
For generic challengers, an Orange Book-listed patent can trigger a Paragraph IV certification and potential litigation under the Hatch-Waxman Act. If Fennec sues within the statutory period, FDA approval of the abbreviated new drug application can be delayed by up to 30 months, subject to court decisions and statutory exceptions.
Publicly available product-level analysis should distinguish among:
- Listed patents covering the approved drug.
- Unlisted process or formulation patents.
- Orphan-drug exclusivity.
- Pediatric exclusivity.
- Regulatory exclusivity that is independent of patent rights.
A patent expiration date alone does not establish the earliest lawful generic launch date. The outcome also depends on Paragraph IV litigation, settlement terms, patent validity, patent scope, and the FDA's exclusivity records.
What generic entry risks exist for Pedmark?
Near-term generic risk is limited by the product's niche market, orphan exclusivity, clinical-use complexity, and potential formulation patents. Long-term risk increases as regulatory exclusivity expires and as generic manufacturers gain access to the sodium thiosulfate market.
Paragraph IV challenge scenarios
A challenger could argue that:
- The relevant formulation claims are obvious.
- The asserted patents lack written description or enablement.
- The claims do not cover the generic product.
- The use claims are invalid or not infringed.
- The generic product can be approved for a non-protected indication.
The strongest generic strategy would likely involve a product that matches the active ingredient while avoiding narrower formulation or dosing claims. Because sodium thiosulfate is an established chemical entity, the inventive strength of the approved product may depend more on formulation, concentration, stability, and clinical-use limitations than on the molecule itself.
Generic launch scenarios
| Scenario |
Commercial effect |
| No challenge before 2029 |
Fennec retains protected orphan market during the core exclusivity period |
| Paragraph IV filing with settlement |
Entry date depends on the negotiated agreement |
| Successful patent challenge |
Potential launch before listed-patent expiration |
| Post-exclusivity generic launch |
Price erosion and hospital formulary substitution risk |
| Competing formulation approval |
May compete without fully replicating Pedmark's commercial presentation |
The market may not experience the same level of price erosion as a high-volume oral generic market. Pediatric oncology purchasing is concentrated, but hospital systems can still demand discounts once alternatives are available.
What biosimilar risk affects Pedmark?
Biosimilar risk is effectively absent because Pedmark is a small-molecule sodium thiosulfate product, not a biologic. Competition would arise through an abbreviated new drug application, a new drug application, or another applicable FDA pathway rather than the biosimilar pathway under the Public Health Service Act.
The relevant competitive risks are generic sodium thiosulfate products, alternative formulations, off-label use, and future otoprotective therapies.
Which companies are challenging Pedmark?
No major publicly established Paragraph IV litigation campaign against Pedmark is central to the product's current commercial profile. The competitive environment is more likely to develop through generic manufacturers assessing formulation and market size than through branded pharmaceutical companies pursuing a direct launch.
Potential challengers would include:
- Generic injectable manufacturers.
- Specialty hospital-product companies.
- Firms with sodium thiosulfate manufacturing capability.
- Oncology-supportive-care companies seeking adjacent products.
The market's small size may delay entry by large generic companies. Specialized injectable manufacturers can still enter if manufacturing economics and hospital contracts justify the investment.
How strong is the Pedmark patent estate?
Pedmark's overall protection is strongest when four layers work together:
- FDA orphan-drug exclusivity.
- Pediatric exclusivity.
- Orange Book-listed product or method patents.
- Manufacturing and formulation know-how.
Patent strength is moderate to strong from a commercial timing perspective if the patents cover the approved formulation and remain enforceable through or beyond the regulatory exclusivity period. It is weaker if protection depends mainly on broad method-of-use claims involving a known active ingredient.
Manufacturing barriers may provide practical protection. Sterile injectable production requires validated facilities, quality systems, stability data, container-closure controls, and reliable hospital supply. Those barriers can slow entry but generally do not replace patent protection.
What licensing deals and partnerships affect Pedmark?
Fennec has retained the central commercial rights to Pedmark in the United States. The company's value is closely tied to its ability to commercialize the product directly, secure reimbursement, and expand use across pediatric oncology centers.
International commercialization can create licensing or distribution opportunities because pediatric cisplatin use and hearing-loss protocols vary by jurisdiction. The European market is relevant because sodium thiosulfate products have received regulatory attention outside the United States, including the European authorization of Pedmarqsi for pediatric cisplatin-associated ototoxicity.[4]
International partnerships could reduce Fennec's direct selling costs but would also reduce net revenue through royalties, milestones, or profit-sharing structures.
What is the competitive outlook for Pedmark?
Pedmark has a differentiated position, but its market is narrow.
| Competitive factor |
Pedmark position |
| Clinical need |
High |
| Patient population |
Small |
| Direct branded competition |
Limited |
| Generic risk before 2029 |
Moderate to low |
| Reimbursement sensitivity |
High |
| Hospital adoption complexity |
Moderate |
| Manufacturing complexity |
Moderate to high |
| Revenue concentration |
Very high |
| Long-term price erosion risk |
Meaningful after exclusivity |
The main commercial risk is not immediate substitution by a branded rival. It is slower-than-expected adoption caused by institutional workflow, payer restrictions, physician concerns regarding tumor control, or inconsistent guideline integration.
Key Takeaways
- Pedmark is Fennec Pharmaceuticals' FDA-approved sodium thiosulfate injection for reducing cisplatin-associated hearing loss in eligible pediatric solid-tumor patients.
- The U.S. approval date was September 20, 2022.
- Orphan-drug exclusivity generally extends through September 2029, subject to statutory exceptions and any applicable pediatric extension.
- The product's market is small but clinically concentrated and commercially defensible.
- Revenue depends on pediatric oncology center adoption, reimbursement, and protocol integration.
- Biosimilar risk does not apply because Pedmark is a small-molecule drug.
- Generic risk will increase as orphan exclusivity expires, particularly if challengers can avoid or invalidate formulation and method patents.
- Fennec's financial exposure is concentrated in a single commercial product.
- Manufacturing, sterile-injectable requirements, and hospital purchasing complexity may slow generic entry but do not eliminate patent risk.
- The most important diligence items are current Orange Book listings, issued patent claims, FDA exclusivity records, quarterly net product revenue, active treatment-center count, gross margin, and any Paragraph IV filings.
FAQs
What cancer patients are eligible for Pedmark?
Pedmark is indicated for pediatric patients at least one month old with localized, nonmetastatic solid tumors receiving cisplatin. The treating oncologist determines eligibility based on tumor type, treatment plan, and label requirements.
Is sodium thiosulfate the same as Pedmark?
No. Sodium thiosulfate is the active ingredient. Pedmark is Fennec's FDA-approved formulation, packaging, labeling, and dosing regimen.
Can hospitals use generic sodium thiosulfate instead of Pedmark?
A hospital may have access to other sodium thiosulfate products, but substitution depends on formulation, concentration, labeling, clinical protocol, pharmacy policy, and reimbursement. A generic product would need appropriate FDA approval for the intended use.
Does Pedmark prevent all cisplatin-related hearing loss?
No. Clinical-trial results show risk reduction, not complete prevention. Outcomes vary by age, cumulative cisplatin exposure, tumor type, timing, and individual susceptibility.
What is the largest long-term risk to Fennec's Pedmark revenue?
The largest risk is concentrated-product exposure. Slower hospital adoption, reimbursement pressure, a successful patent challenge, or generic entry after regulatory exclusivity could materially reduce revenue because Pedmark is Fennec's principal commercial asset.
References
- U.S. Food and Drug Administration. (2022). FDA approves sodium thiosulfate to reduce the risk of ototoxicity associated with cisplatin in pediatric patients with localized, nonmetastatic solid tumors.
- Fennec Pharmaceuticals, Inc. (2024). Annual report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934.
- U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations: Orange Book.
- European Medicines Agency. (2023). Pedmarqsi: EPAR product information.
